Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041470 · ClinicalTrials.gov registry record · Phase 1
Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00041470 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 38 participants.
The verdict
NCT00041470, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purposes of this are: * To determine the highest doses of Taxol and Navelbine that we can safely give to patients; * To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF; * To determine whether the combination of Taxol, Navelbine and G-CSF is more effective than standard therapy in treating metastatic breast cancer and prolonging life;
Interventions
- DRUG Paclitaxel
- DRUG Filgrastim
- DRUG Vinorelbine
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2001-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041470
The ClinicalTrials.gov registry entry for NCT00041470 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT00041470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041470 about?
NCT00041470 is a clinical study titled "Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial". The purposes of this are: * To determine the highest doses of Taxol and Navelbine that we can safely give to patients; * To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF; * To determine whether the combination of Taxol, Navelbine and G-CSF is more e...
What is the current status of trial NCT00041470?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2001-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00041470?
The interventions under investigation include: Paclitaxel (DRUG), Filgrastim (DRUG), Vinorelbine (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00041470?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.